ClinVar Miner

Submissions for variant NM_000040.3(APOC3):c.55+1G>A

gnomAD frequency: 0.00153  dbSNP: rs138326449
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001401913 SCV001603751 likely benign not provided 2023-10-06 criteria provided, single submitter clinical testing
GeneDx RCV001401913 SCV001771311 uncertain significance not provided 2022-05-16 criteria provided, single submitter clinical testing Canonical splice site variant; heterozygous loss-of-function variants in the APOC3 gene have been reported in association with hypotriglyceridemia and protection against cardiovascular disease; This variant is associated with the following publications: (PMID: 23701270, 25225788, 24941082, 28008009, 27114411, 24941081, 30405126, 30255797, 27146844, 29348120, 31589614, 34426522, 32041611, 28787443, 23685560, 34834584)
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002271410 SCV002555652 likely benign not specified 2023-07-24 criteria provided, single submitter clinical testing Variant summary: APOC3 c.55+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a canonical 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0014 in 250966 control chromosomes (gnomAD). The observed variant frequency is approximately 70-fold of the estimated maximal expected allele frequency for a pathogenic variant in APOC3 causing Early Onset Coronary Artery Disease phenotype (2e-05), suggesting that the variant is not associated with Early Onset Coronary Artery Disease. c.55+1G>A has been reported in the literature in association with reduced levels of triglycerides and increased levels of HDL in heterozygous individuals and was shown to result in an atheroprotective lipid profile with lowered risk of coronary heart disease (Bochem_2014, Crosby_2014, Jorgensen_2014, Timpson_2014, Goyal_2021). The following publications have been ascertained in the context of this evaluation (PMID: 23701270, 30255797, 24941081, 27114411, 32041611, 34548093, 24941082, 25225788). Three submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as VUS (n=2) and likely benign (n=1). Based on the evidence outlined above, the variant was classified as likely benign.
Ambry Genetics RCV002345442 SCV002648646 uncertain significance Cardiovascular phenotype 2021-12-21 criteria provided, single submitter clinical testing The c.55+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 1 of the APOC3 gene. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. However, the evidence for this gene-disease relationship is limited; therefore, the clinical significance of this alteration is unclear.
Department Of Human Genetics, Institute Of Clinical And Translational Research, Biomedical Research Center, Slovak Academy Of Sciences RCV000148017 SCV004227982 likely pathogenic Apolipoprotein c-III deficiency criteria provided, single submitter research This APOC3 splicing variant NM_000040.3:c.55+1G>A (rs138326449) was described for the first time in PMID: 23701270 and has been associated with decreased plasma triglyceride and apoC-III levels. Normally it has been reported to show an atheroprotective effect (see also PMID: 24941081; PMID: 24941081; PMID: 25225788; PMID: 25962519; PMID: 27114411; PMID: 30255797; PMID: 32041611; PMID: 34548093). We report this variant in a 57-year-old male patient with combined hypolipidaemia, who presented with premature peripheral vascular disease, and also in one of his two sons, 32-years-old. Both individuals manifested decreased TG levels (between the 10th and 25th centiles). The atheroprotective effect has not been seen in the patients, most likely because they also carried a novel ABCA1 variant NM_005502.4:c.1857_1858delinsAT, possibly responsible for their decreased HDL levels (see PMID: 36876364). The effect of the APOC3 splicing variant on TG levels is further confirmed by the evidence, that the second son, 32-years-old, who carried the ABCA1 variant but not the APOC3 variant, had TG values between 75th and 90th centiles. This variant is listed as a disease-causing in the HGMD database (CS138510) and GnomAD Exomes Version: 4.0 indicates the frequency of ƒ = 0.00199.
ClinVar Staff, National Center for Biotechnology Information (NCBI) RCV000128449 SCV000172131 protective Coronary heart disease 2014-06-18 no assertion criteria provided literature only
OMIM RCV000148017 SCV000195517 pathogenic Apolipoprotein c-III deficiency 2014-07-03 flagged submission literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.